a kinase of the PLK family. Contains a polo-box domain (PBD), a specific phosphoserine or phosphothreonine binding domain. Substrates include BRCA2, Myt1, NudC, Cdc25C, cyclin B1, Nlp and other mitotic proteins. Inhibited by ATR. Plays a role in regulation of cytokinesis and coordinating M-phase events. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, Other; EC 220.127.116.11; Protein kinase, Ser/Thr (non-receptor); Kinase, protein; Other group; PLK family
Molecular Function: kinase activity; microtubule binding; protein binding; protein kinase activity; protein kinase binding; protein serine/threonine kinase activity
Biological Process: anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; cell proliferation; centrosome organization and biogenesis; cytokinesis; cytokinesis after mitosis; establishment of protein localization; G2/M transition DNA damage checkpoint; G2/M transition of mitotic cell cycle; microtubule bundle formation; mitosis; mitotic cell cycle spindle assembly checkpoint; mitotic nuclear envelope disassembly; mitotic sister chromatid segregation; negative regulation of apoptosis; negative regulation of cyclin-dependent protein kinase activity; negative regulation of transcription from RNA polymerase II promoter; peptidyl-serine phosphorylation; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of proteolysis; positive regulation of ubiquitin-protein ligase activity; positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; protein amino acid phosphorylation; protein destabilization; protein ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; regulation of cell cycle; regulation of mitotic cell cycle; regulation of mitotic metaphase/anaphase transition; regulation of protein binding; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; sister chromatid cohesion
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.